Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

類似資料

• Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
  著者:: Smith, Mitchell R., 等
  出版事項: (2012)
• VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
  著者:: Chang, J. E., 等
  出版事項: (2011)
• VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study
  著者:: Chang, J.E., 等
  出版事項: (2017)
• Mantle Cell Lymphoma Initial Therapy with Abbreviated R-CHOP Followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the Phase 2 ECOG-ACRIN study E1499
  著者:: Smith, Mitchell R., 等
  出版事項: (2016)
• A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
  著者:: Bernstein, S. H., 等
  出版事項: (2013)